Lorlatinib + Rifampin Interaction
Contraindicatedinteraction on record
Description
Severe hepatotoxicity occurred in healthy subjects receiving lorlatinib with rifampin (a strong CYP3A inducer). Grade 3-4 ALT/AST increases occurred in 83% of subjects.
Mechanism
CYP3A induction and PXR agonism activation by both drugs
Source: NLP:lorlatinib